\-\ Texto\\:\\ \ \(0\)\
\-\ laboratory\\:\ \(3\)\
\-\ \\ \\ \\ \\(22apr2004\\)\\ ft4\\:\\ 2\\.11\\ ng\\/dl\\ \\ \\ \\(0\\.89\\-1\\.80\\ ng\\/dl\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ tsh\\:\\ undetectable\\ \\(0\\.35\\-5\\.50\\ uiu\\/ml\\)\ \(0\)\
\-\ \\ \\ \\ \\(10may2004\\)\\ ft4\\:\\ 1\\.26\\ ng\\/dl\\ \\ \\(0\\.89\\-1\\.80\\ ng\\/dl\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ tsh\\:\\ \\<0\\.08\\ uiu\\/ml\\ \\(0\\.35\\-5\\.50\\ uiu\\/ml\\)\ \(0\)\
\-\ pe\\:\\(11may2004\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ no\\ palpable\\ nodules\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ no\\ thyroid\\ enlargement\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ no\\ tenderness\ \(0\)\
\-\ the\\ treatment\\ is\\ observation\\ and\\ allowing\\ the\\ patient\\ to\\ return\\ to\\ normal\\,\\ along\\ with\\ symptomatic\\ treatment\\.\\ \\ the\\ disease\\ is\\ almost\\ always\\ self\\ limiting\\ with\\ no\\ adverse\\ sequelae\\,\\ but\\ occasionally\\ it\\ recurs\\ and\\ may\\ result\\ in\\ permanent\\ hypothyroidism\\.\ \(0\)\
\-\ dose\\:\\ \\ \\ 4\\.86\\ uci\\ i\\-131\\,\\ po\\.\ \(0\)\
\-\ \\ \\	4\\.65\\ mci\\ tc99m\\-pertechnatate\\,\\ iv\\.\ \(0\)\
\-\ procedure\\:\\ \\ approximately\\ 24\\ hours\\ prior\\ to\\ imaging\\,\\ patient\\ was\\ given\\ iodine\\-131\\ po\\.\\ \\ uptake\\ was\\ calculated\\ with\\ iodine\\-131\\ probe\\ detector\\ at\\ four\\ hours\\ and\\ again\\ at\\ 24\\ hours\\.\\ \\ after\\ 24\\-hour\\ uptake\\ was\\ obtained\\,\\ patient\\ was\\ injected\\ with\\ tc\\-99m\\ pertechnetate\\ and\\ planar\\ images\\ and\\ pinhole\\ collimator\\ images\\ were\\ obtained\\ of\\ the\\ thyroid\\.\ \(0\)\
\-\ i\\-131\\ uptake\\:\\	\\ 4\\ hour\\ \\ \\ 3\\.1\\%\\ \\(2\\-12\\%\\)\ \(0\)\
\-\ \\	\\	24\\ hour\\ \\ \\ 4\\.7\\%\\ \\(12\\-30\\%\\)\ \(1\)\
\-\ 24\\ hour\\ tc\\-99m\\ scan\\(11may2004\\)\\:\\ \\ decreased\\ but\\ otherwise\\ physiologic\\-appearing\\ uptake\\.\\ given\\ the\\ amount\\ of\\ background\\ activity\\ and\\ the\\ subsequent\\ decreased\\ target\\ to\\ background\\ ratio\\,\\ the\\ scan\\ demonstrates\\ decreased\\ uptake\\ in\\ the\\ thyroid\\.\ \(0\)\
\-\ subacute\\ thyroiditis\ \(5\)\
\-\ subacute\\ thyroiditis\ \(5\)\
\-\ thyrotoxicosis\\ factitia\ \(0\)\
\-\ hyperthyroidism\\ caused\\ by\\ iodine\\ ingestion\\ \\(e\\.g\\.\\ amiodarone\\,\\ iodine\\-rich\\ contrast\\ agents\\)\ \(0\)\
\-\ struma\\ ovarii\ \(1\)\
\-\ 43\\ y\\/o\\ female\\ with\\ acute\\ onset\\ of\\ agitation\\,\\ heat\\ intolerance\\ and\\ loose\\ stools\\,\\ approximately\\ two\\ weeks\\ ago\\ \\(prior\\ to\\ the\\ day\\ of\\ thyroid\\ uptake\\/scan\\)\\.\\ upon\\ questioning\\ on\\ day\\ of\\ scan\\,\\ relates\\ having\\ an\\ upper\\ respiratory\\ infection\\ 4\\-5\\ weeks\\ prior\\ to\\ having\\ symptoms\\.\ \(0\)\
\-\ see\\ factoid\\.\ \(59\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ng\\/dl\\:\\ 0\\.0782507930338044\ \(0\)\
\-\ uiu\\/ml\\:\\ 0\\.06210984633421309\ \(0\)\
\-\ 0\\.89\\-1\\.80\\:\\ 0\\.0597662266031627\ \(0\)\
\-\ 0\\.35\\-5\\.50\\:\\ 0\\.0597662266031627\ \(0\)\
\-\ 11may2004\\:\\ 0\\.0597662266031627\ \(0\)\
\-\ iodine\\-131\\:\\ 0\\.0597662266031627\ \(0\)\
\-\ uptake\\:\\ 0\\.0575420919439697\ \(0\)\
\-\ hour\\:\\ 0\\.0475157664160166\ \(0\)\
\-\ thyroid\\:\\ 0\\.04748898230406387\ \(0\)\
\-\ 24\\:\\ 0\\.04505026414408067\ \(0\)\
\-\ i\\-131\\:\\ 0\\.04017048587166328\ \(0\)\
\-\ ft4\\:\\ 0\\.03945617729093225\ \(0\)\
\-\ \\:\\:\\ 0\\.03831440054205644\ \(0\)\
\-\ background\\:\\ 0\\.03794333965490371\ \(0\)\
\-\ thyroiditis\\:\\ 0\\.03648495742021256\ \(0\)\
\-\ hours\\:\\ 0\\.034171498053648774\ \(0\)\
\-\ po\\:\\ 0\\.033109781635540146\ \(0\)\
\-\ tc\\-99m\\:\\ 0\\.033109781635540146\ \(0\)\
\-\ tsh\\:\\ 0\\.03146529595980244\ \(0\)\
\-\ 22apr2004\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ 2\\.11\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ 10may2004\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ 1\\.26\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ 4\\.86\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ 4\\.65\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ tc99m\\-pertechnatate\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ physiologic\\-appearing\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ factitia\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ uptake\\/scan\\:\\ 0\\.02988311330158135\ \(0\)\
\-\ subacute\\:\\ 0\\.029726790678801247\ \(0\)\
\-\ \\(\\:\\ 0\\.02938420581330958\ \(0\)\
\-\ \\)\\:\\ 0\\.029025262052066646\ \(0\)\
\-\ recurs\\:\\ 0\\.02753346184205611\ \(0\)\
\-\ iodine\\-rich\\:\\ 0\\.02753346184205611\ \(0\)\
\-\ \\%\\:\\ 0\\.02702808180808146\ \(0\)\
\-\ having\\:\\ 0\\.026611317259286404\ \(0\)\
\-\ detector\\:\\ 0\\.02615900384846911\ \(0\)\
\-\ collimator\\:\\ 0\\.02615900384846911\ \(0\)\
\-\ decreased\\:\\ 0\\.025838200705673484\ \(0\)\
\-\ undetectable\\:\\ 0\\.025183810382530872\ \(0\)\
\-\ relates\\:\\ 0\\.025183810382530872\ \(0\)\
\-\ 12\\-30\\:\\ 0\\.024427391564516603\ \(0\)\
\-\ scan\\:\\ 0\\.02432818434338622\ \(0\)\
\-\ ovarii\\:\\ 0\\.023809352388943873\ \(0\)\
\-\ struma\\:\\ 0\\.02328680771156334\ \(0\)\
\-\ probe\\:\\ 0\\.022834158923005634\ \(0\)\
\-\ 4\\.7\\:\\ 0\\.022834158923005634\ \(0\)\
\-\ agitation\\:\\ 0\\.022834158923005634\ \(0\)\
\-\ uci\\:\\ 0\\.022434894395356876\ \(0\)\
\-\ pinhole\\:\\ 0\\.022434894395356876\ \(0\)\
\-\ prior\\:\\ 0\\.022313011242735898\ \(0\)\
\-\ 0\\.08\\:\\ 0\\.022077740104991365\ \(0\)\
\-\ amiodarone\\:\\ 0\\.022077740104991365\ \(0\)\
\-\ 24\\-hour\\:\\ 0\\.021459700929418634\ \(0\)\
\-\ thyrotoxicosis\\:\\ 0\\.021188369716965968\ \(0\)\
\-\ questioning\\:\\ 0\\.021188369716965968\ \(0\)\
\-\ adverse\\:\\ 0\\.0209371562520381\ \(0\)\
\-\ calculated\\:\\ 0\\.0209371562520381\ \(0\)\
\-\ pertechnetate\\:\\ 0\\.0209371562520381\ \(0\)\
\-\ 2\\-12\\:\\ 0\\.0209371562520381\ \(0\)\
\-\ obtained\\:\\ 0\\.020595702377924352\ \(0\)\
\-\ given\\:\\ 0\\.01986043655943283\ \(0\)\
\-\ limiting\\:\\ 0\\.019728088645466126\ \(0\)\
\-\ 3\\.1\\:\\ 0\\.0195626982584511\ \(0\)\
\-\ self\\:\\ 0\\.019405003290197228\ \(0\)\
\-\ stools\\:\\ 0\\.019254319349279146\ \(0\)\
\-\ 4\\-5\\:\\ 0\\.019254319349279146\ \(0\)\
\-\ mci\\:\\ 0\\.01883871825744073\ \(0\)\
\-\ planar\\:\\ 0\\.01883871825744073\ \(0\)\
\-\ allowing\\:\\ 0\\.01871078494224464\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.01871078494224464\ \(0\)\
\-\ permanent\\:\\ 0\\.018587504792512862\ \(0\)\
\-\ day\\:\\ 0\\.01839294799561308\ \(0\)\
\-\ iodine\\:\\ 0\\.01824247871010628\ \(0\)\
\-\ heat\\:\\ 0\\.018134856003955157\ \(0\)\
\-\ intolerance\\:\\ 0\\.018030545296610228\ \(0\)\
\-\ injected\\:\\ 0\\.017929348811357073\ \(0\)\
\-\ approximately\\:\\ 0\\.01792418865461412\ \(0\)\
\-\ ingestion\\:\\ 0\\.01764271359770262\ \(0\)\
\-\ target\\:\\ 0\\.017464260263853736\ \(0\)\
\-\ sequelae\\:\\ 0\\.017213046798925862\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.01697917265829213\ \(0\)\
\-\ agents\\:\\ 0\\.01697917265829213\ \(0\)\
\-\ loose\\:\\ 0\\.01683176549917437\ \(0\)\
\-\ weeks\\:\\ 0\\.016442561063736597\ \(0\)\
\-\ ratio\\:\\ 0\\.0160609524747823\ \(0\)\
\-\ 43\\:\\ 0\\.015629917981611976\ \(0\)\
\-\ e\\.g\\:\\ 0\\.015339182992603752\ \(0\)\
\-\ occasionally\\:\\ 0\\.01524756037433962\ \(0\)\
\-\ dose\\:\\ 0\\.015158349159704454\ \(0\)\
\-\ always\\:\\ 0\\.014903992597186102\ \(0\)\
\-\ observation\\:\\ 0\\.014863395339400624\ \(0\)\
\-\ return\\:\\ 0\\.014667396794014775\ \(0\)\
\-\ almost\\:\\ 0\\.014011482023194164\ \(0\)\
\-\ again\\:\\ 0\\.013918604144590388\ \(0\)\
\-\ was\\:\\ 0\\.013400373182558465\ \(0\)\
\-\ pe\\:\\ 0\\.013012829428969232\ \(0\)\
\-\ four\\:\\ 0\\.012574823559545483\ \(0\)\
\-\ but\\:\\ 0\\.012355954583278221\ \(0\)\
\-\ caused\\:\\ 0\\.012150541719023428\ \(0\)\
\-\ procedure\\:\\ 0\\.012132462580123895\ \(0\)\
\-\ amount\\:\\ 0\\.012096591023071228\ \(0\)\
\-\ respiratory\\:\\ 0\\.012025966999671763\ \(0\)\
\-\ nodules\\:\\ 0\\.012008538526788988\ \(0\)\
\-\ upon\\:\\ 0\\.011839011677383356\ \(0\)\
\-\ treatment\\:\\ 0\\.01172621667526025\ \(0\)\
\-\ no\\:\\ 0\\.011667039331576977\ \(0\)\
\-\ symptomatic\\:\\ 0\\.01150841838879394\ \(0\)\
\-\ enlargement\\:\\ 0\\.011493452225373204\ \(0\)\
\-\ subsequent\\:\\ 0\\.011276544738338345\ \(0\)\
\-\ \\<\\:\\ 0\\.011179883144073866\ \(0\)\
\-\ images\\:\\ 0\\.011113653504741383\ \(0\)\
\-\ result\\:\\ 0\\.01111248866762021\ \(0\)\
\-\ activity\\:\\ 0\\.010867954673835724\ \(0\)\
\-\ ago\\:\\ 0\\.010782131595922876\ \(0\)\
\-\ laboratory\\:\\ 0\\.010674887240183274\ \(0\)\
\-\ iv\\:\\ 0\\.010570931991393537\ \(0\)\
\-\ otherwise\\:\\ 0\\.010404458418394389\ \(0\)\
\-\ palpable\\:\\ 0\\.01026651200881285\ \(0\)\
\-\ factoid\\:\\ 0\\.010154018622420801\ \(0\)\
\-\ \\,\\:\\ 0\\.010094273629458174\ \(0\)\
\-\ along\\:\\ 0\\.009573063989350901\ \(0\)\
\-\ onset\\:\\ 0\\.009143800765847965\ \(0\)\
\-\ tenderness\\:\\ 0\\.008809872280954688\ \(0\)\
\-\ patient\\:\\ 0\\.008711104382200555\ \(0\)\
\-\ to\\:\\ 0\\.008686131019179382\ \(0\)\
\-\ see\\:\\ 0\\.008644804105860299\ \(0\)\
\-\ infection\\:\\ 0\\.008420395166348498\ \(0\)\
\-\ two\\:\\ 0\\.008296038093613579\ \(0\)\
\-\ 4\\:\\ 0\\.008071091203996763\ \(0\)\
\-\ y\\/o\\:\\ 0\\.008022471287524206\ \(0\)\
\-\ at\\:\\ 0\\.007849241714112765\ \(0\)\
\-\ symptoms\\:\\ 0\\.007219177887790302\ \(0\)\
\-\ acute\\:\\ 0\\.007152133319005069\ \(0\)\
\-\ upper\\:\\ 0\\.006990103408029554\ \(0\)\
\-\ imaging\\:\\ 0\\.006786690930357975\ \(0\)\
\-\ were\\:\\ 0\\.006577241819287869\ \(0\)\
\-\ it\\:\\ 0\\.006511350456044124\ \(0\)\
\-\ contrast\\:\\ 0\\.006483985379009848\ \(0\)\
\-\ may\\:\\ 0\\.00635365548779025\ \(0\)\
\-\ demonstrates\\:\\ 0\\.006327529497129444\ \(0\)\
\-\ after\\:\\ 0\\.005993224415624415\ \(0\)\
\-\ female\\:\\ 0\\.005955119564229944\ \(0\)\
\-\ by\\:\\ 0\\.004823291197440253\ \(0\)\
\-\ disease\\:\\ 0\\.004734703529544759\ \(0\)\
\-\ normal\\:\\ 0\\.004541059168132546\ \(0\)\
\-\ and\\:\\ 0\\.004271400136018743\ \(0\)\
\-\ the\\:\\ 0\\.004217774787568245\ \(0\)\
\-\ an\\:\\ 0\\.004005643607744846\ \(0\)\
\-\ is\\:\\ 0\\.0038121408704049195\ \(0\)\
\-\ in\\:\\ 0\\.0028569303738322366\ \(0\)\
\-\ on\\:\\ 0\\.002453867838526875\ \(0\)\
\-\ with\\:\\ 0\\.001983121628642199\ \(0\)\
\-\ of\\:\\ 0\\.001974640691491329\ \(0\)\
\-\ \\.\\:\\ 0\\.0015643863364932257\ \(0\)\
